MONITORING THE COMPARATIVE SAFETY OF SGLT2I VS GLP-1 RA IN OLDER ADULTS WITH TYPE 2 DIABETES BY FRAILTY STATUS

被引：0
|
作者：
Kutz, Alexander [1 ]
Patorno, Elisabetta [2 ,3 ]
Gopalakrishnan, Chandrasekar [2 ,3 ]
Kim, Dae [4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Hebrew SeniorLife, Boston, MA USA
来源：
INNOVATION IN AGING | 2021年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [21] The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes
    Ohara, Masaya
    Motoyama, Koka
    Tamai, Anna
    Sakura, Takeshi
    Yakushiji, Yosuke
    Hosoi, Masayuki
    DIABETES, 2019, 68
  • [22] Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
    de Carvalho, Francisco Simoes
    Marques, Francisca de Brito
    Lopes, Ana Elisa
    Ferreira, Joana Lima
    Principe, Rosa Maria
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [23] The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study
    Wu, Tingting
    Wong, Carlos K. H.
    Tang, Eric H. M.
    Man, Kenneth K. C.
    Wong, Simon K. H.
    Au, Ivan Chi Ho
    Tse, Emily T. Y.
    Chan, Esther W. Y.
    Grieve, Eleanor
    Wu, Olivia
    Ng, Enders K. W.
    Wong, Ian C. K.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2022, 18 (06) : 762 - 771
  • [24] SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)
    Nguyen, Julia
    Nee, Robert
    Marneweck, Hava
    Banaag, Amanda
    Koehlmoos, Tracey
    Oliver, James
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [25] Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes
    Yanus, Matthew R.
    Saleni, Angela
    Bhavsar, Riya
    Zhang, Tony
    McCane, Charles D.
    Pan, Alan P.
    Vahidy, Farhaan
    Gadhia, Rajan R.
    STROKE, 2024, 55
  • [26] Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 591 - 591
  • [27] Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
    Luo, Jing
    Gabriel, Nico
    Korytkowski, Mary
    Hernandez, Inmaculada
    Gellad, Walid F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 187
  • [28] Glycaemic control and beta cell function in type 2 diabetes on SGLT2i and GLP-1RA combination therapy
    Martinez, R.
    Al-Jobory, H.
    Adams, J.
    Chavez-Velasquez, A.
    Triplitt, C.
    DeFronzo, R. A.
    Cersosimo, E.
    DIABETOLOGIA, 2017, 60 : S408 - S409
  • [29] Cost Effectiveness of Using DPP-4i and SGLT2i Combination Therapy vs. Switching to GLP-1 Therapy for the Management of Type 2 Diabetes
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Davies, Glenn M.
    DIABETES, 2019, 68
  • [30] Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020
    Mittman, Benjamin G.
    Le, Phuc
    Payne, Julia Y.
    Ayers, Gina
    Rothberg, Michael B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (03) : 377 - 383
12345